Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29205137 | 0.90 | NAMPT (0.40) | NAMPTELANECDK1MYT1SPR | |
| SCHEMBL30054983 | 0.87 | NAMPT (0.38) | NAMPTELANEGRM5CDK1MYT1 | |
| SCHEMBL27166046 | 0.87 | NAMPT (0.38) | NAMPTELANEGRM5CDK1MYT1 | |
| SCHEMBL27166156 | 0.84 | MAPK14 (0.41) | NAMPTELANEGRM5SPRSOS1 | |
| SCHEMBL27166049 | 0.84 | PROKR1 (0.41) | NAMPTELANECDK1MYT1SPR | |
| SCHEMBL29205155 | 0.81 | NAMPT (0.38) | NAMPTELANECDK1MYT1SPR | |
| SCHEMBL29205134 | 0.81 | PROKR1 (0.45) | NAMPTELANESCN9A | |
| SCHEMBL27166169 | 0.78 | DPP4 (0.39) | ELANEGRM5MYT1 | |
| SCHEMBL29205125 | 0.78 | ALDH1A1 (0.37) | — | |
| SCHEMBL30056225 | 0.77 | NAMPT (0.34) | NAMPTELANEGRM5CDK1MYT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | ORGANON R&D FINLAND LTD. (FI) | 2024-08-01 | — | — | US | disclosed |
| CN-117794899-A | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | 欧加农研发芬兰有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4334289-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Ltd (FI) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022234193-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | FORENDO PHARMA LTD (FI) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | AKR1C3, AKR1C4, AKR1C1 | NAMPT 602/4885ELANE 2466/4885GRM5 1351/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | NAMPT 2385/4885ELANE 2531/4885GRM5 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.